# Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

Study · id `cardio:ct-nct04270760` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04270760](<https://clinicaltrials.gov/study/NCT04270760>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04270760

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 281 participants.

## Technical summary

Registry record NCT04270760. Randomized; double masking; primary purpose treatment. Start 2020-07-28 (actual); primary completion 2021-12-27 (actual). Results posted on 2023-08-23.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 281 participants (enrolled count; ClinicalTrials.gov record NCT04270760, source copy `cardio:ctgov-nct04270760-2026-03-31`, retrieved 2026-10-31)
- Started: 2020-07-28 (actual) (ClinicalTrials.gov record NCT04270760, source copy `cardio:ctgov-nct04270760-2026-03-31`, retrieved 2026-10-31)
- Primary completion: 2021-12-27 (actual) (ClinicalTrials.gov record NCT04270760, source copy `cardio:ctgov-nct04270760-2026-03-31`, retrieved 2026-10-31)
- Completion: 2022-11-08 (actual) (ClinicalTrials.gov record NCT04270760, source copy `cardio:ctgov-nct04270760-2026-03-31`, retrieved 2026-10-31)
- Results first posted: 2023-08-23 (ClinicalTrials.gov record NCT04270760, source copy `cardio:ctgov-nct04270760-2026-03-31`, retrieved 2026-10-31)
- Countries: United States; Australia; Canada; Denmark; Iceland; Japan; Netherlands (ClinicalTrials.gov record NCT04270760, source copy `cardio:ctgov-nct04270760-2026-03-31`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04270760-2026-03-31`, retrieved 2026-10-31)

## The registry's words

- Brief title: Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
- Condition: Cardiovascular Disease
- Intervention (Drug): Olpasiran
- Intervention (Drug): Placebo
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: e03964024d9fc79e419274cc2fbef653d2a1f6a582aa1556081d15893e8f62a9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
